A Review of Autologous Stem Cell Transplantation in Lymphoma.

Research paper by Umar U Zahid, Faisal F Akbar, Akshay A Amaraneni, Muhammad M Husnain, Onyee O Chan, Irbaz Bin IB Riaz, Ali A McBride, Ahmad A Iftikhar, Faiz F Anwer

Indexed on: 10 May '17Published on: 10 May '17Published in: Current Hematologic Malignancy Reports


Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20-30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients.There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.